Nuevo topico para DA

New Eczema Treatment Approved

By the Editors

The FDA has approved crisaborole ointment (marketed as Eucrisa) to treat mild-to-moderate atopic dermatitis in patients aged 2 years and older.

The phosphodiesterase 4 (PDE-4) inhibitor is applied to the affected area twice daily. The FDA says its mechanism of action in treating atopic dermatitis is unknown.

Approval was based on two placebo-controlled trials comprising over 1500 patients aged 2 to 79 years. Those who used crisaborole had a greater treatment response after 4 weeks of treatment.

The most common side effect was local pain, such as stinging. Hypersensitivity reactions also may occur.

FDA news release (Free)

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.